欧洲食管胃癌寡转移定义、诊断与治疗临床实践指南(OMEC-4)
该指南依据AGREE II与GRADE原则制定,基于系统综述、病例讨论和Delphi共识研究,由49个欧洲专家中心参与。指南明确了食管胃寡转移病的定义标准,推荐18F-FDG PET/CT用于基线分期及再分期,并根据异时性寡转移的无病间期是否超过2年区分治疗策略。
要点
- 寡转移定义为1个器官≤3个转移灶或1个区域外淋巴结站受累。
- 18F-FDG PET/CT推荐用于基线分期及系统治疗后的再分期。
- 同步寡转移或异时性寡转移无病间期≤2年者推荐系统治疗后重新分期再评估局部治疗。
核心结论
- 该指南为食管胃寡转移病的统一定义、诊断和治疗提供多学科欧洲临床实践推荐,可用于规范未来临床试验的入组标准并减少治疗差异。
研究设计与样本
- 指南依据AGREE II和GRADE原则制定,基于系统综述(OMEC-1)、临床病例讨论(OMEC-2)和Delphi共识研究(OMEC-3),由49个欧洲食管胃癌专家中心参与。
主要发现
- 证据质量为中等至高等,包括1项随机和4项非随机II期试验,据此形成中等强度推荐。
- 寡转移病考虑见于食管胃癌患者中1个器官≤3个转移灶或1个区域外淋巴结站受累者。
- 系统治疗后转移灶数目无进展的寡转移病患者继续考虑为寡转移病。
关键数值与推荐
- 推荐18F-FDG PET/CT用于基线分期及考虑局部治疗时系统治疗后的再分期。
- 同步寡转移或异时性寡转移且无病间期≤2年者,推荐治疗为系统治疗后继以重新分期以评估局部治疗适宜性。
- 异时性寡转移且无病间期>2年者,额外推荐 upfront 局部治疗。
临床怎么用
- 原文未据此给出临床实践推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The OligoMetastatic Esophagogastric Cancer (OMEC) project aims to provide clinical practice guidelines for the definition, diagnosis, and treatment of esophagogastric oligometastatic disease (OMD). METHODS: Guidelines were developed according to AGREE II and GRADE principles. Guidelines were based on a systematic review (OMEC-1), clinical case discussions (OMEC-2), and a Delphi consensus study (OMEC-3) by 49 European expert centers for esophagogastric cancer. OMEC identified patients for whom the term OMD is considered or could be considered. Disease-free interval (DFI) was defined as the time between primary tumor treatment and detection of OMD. RESULTS: Moderate to high quality of evidence was found (i.e. 1 randomized and 4 non-randomized phase II trials) resulting in moderate recommendations. OMD is considered in esophagogastric cancer patients with 1 organ with ≤ 3 metastases or 1 involved extra-regional lymph node station. In addition, OMD continues to be considered in patients with OMD without progression in number of metastases after systemic therapy. 18F-FDG PET/CT imaging is recommended for baseline staging and for restaging after systemic therapy when local treatment is considered. For patients with synchronous OMD or metachronous OMD and a DFI ≤ 2 years, recommended treatment consists of systemic therapy followed by restaging to assess suitability for local treatment. For patients with metachronous OMD and DFI > 2 years, upfront local treatment is additionally recommended. DISCUSSION: These multidisciplinary European clinical practice guidelines for the uniform definition, diagnosis and treatment of esophagogastric OMD can be used to standardize inclusion criteria in future clinical trials and to reduce variation in treatment.
引用
- Kroese TE, Bronzwaer S, van Rossum PSN, et al. European clinical practice guidelines for the definition, diagnosis, and treatment of oligometastatic esophagogastric cancer (OMEC-4). Eur J Cancer. 2024. PMID: 38678762. doi:10.1016/j.ejca.2024.114062
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。